The principal objective of toxicokinetic studies is to assess systemic exposure of the toxicity species to test compound during nonclinical toxicity studies by generation of pharmacokinetic data on the rate, extent, and duration of exposure. Toxicokinetics are normally integrated within the toxicity studies (concomitant); however, there are a number of circumstances when prospective, retrospective, or other ancillary types of toxicokinetic studies are performed in support of toxicity studies. The need for retrospective toxicokinetic studies arises when the original toxicity study was conducted with insufficient plasma concentration determinations, especially when pilot toxicity studies show lack of toxicity or unusual organ toxicities. Examples of ancillary toxicokinetic studies from the Drug Metabolism and Drug Safety departments at The R. W. Johnson Pharmaceutical Research Institute and from the scientific literature are provided that highlight the challenges associated with these alternate approaches. Each example includes a discussion of the rationale for the supportive toxicokinetic study, the specific experimental designs, the data interpretation, and the usefulness of the toxicokinetic data in decision-making. The ancillary toxicokinetic studies cited provided important information on establishing systemic exposure during long-term toxicity studies, allowing comparisons to human exposures, elucidating compound-related toxicities, and explaining lack of toxicity due to autoinduction and resulting low levels of parent compound.
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In recent years, a number of definitions of toxicokinetics have emerged. Among these is the definition by Chasseaud in Drug Toxicokinetics (2) , &dquo;The primary purpose of toxicokinetics is to provide information on the rate, extent, and duration of exposure of the test animal species to the test compound during the course of a toxicity study.&dquo; Another useful definition appears in the Note for Guidance entitled, &dquo;Draft Guideline on the Assessment of Systemic Exposure in Toxicity Studies,&dquo; from the International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use, which was recently published for comment in the Federal Register (7) . This Note for Guidance defines toxicokinetics as &dquo;the generation of pharmacokinetic data, either as an integral component in the conduct of nonclinical toxicity studies or in specially designed supportive studies, in order to assess systemic exposure.&dquo; The determination of toxicokinetics is normally integrated within the toxicity studies (concomitant) ; however, there are a number of circumstances when retrospective, prospective, or other an-cillary types of toxicokinetic studies are performed to support toxicity studies.
Toxicokinetics as a discipline and as an accepted component of a drug safety program has been evolving over the past few years. This, coupled with the changing regulatory climate and evolving drug de- velopment philosophies of pharmaceutical companies, has resulted in pharmaceutical companies compiling New Drug Applications with insufficient toxicokinetic data. This occurs when a compound has been under development for a relatively long amples of inappropriate toxicokinetic support in-, clude toxicity studies in which no plasma samples were taken for concentration determination or exclusively single timepoints (C&dquo;,ax, trough, etc.) were sampled. In some cases, the necessary analytical . technology for determining plasma concentrations was not in place at the time of the toxicity study. It is also possible that the original toxicokinetic value derived during the toxicity study may be questioned due to subsequent discovery of a metabolite that interferes with the analytical assay or nonspecificity of a radioimmunoassay. One of the challenges associated with retrospective studies is duplicating the : design of the original toxicology studies with respect to dosage levels and regimen, route of administration, formulation, strain/source of animals, and environmental conditions. One must keep in mind that these ancillary studies need to be conducted according to Good Laboratory Practices.
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idene)-~3-D-fructopyranose sulfamate (Fig. 1 ), which is a novel and structurally unique anticonvulsant that has been under preclinical and clinical development at The R. W. Johnson Pharmaceutical Research Institute for the treatment of epilepsy for approximately 10 yr. As part of the preclinical safety program, the 2-yr mouse carcinogenicity study was conducted by the Drug Safety Evaluation Department by administering topiramate daily as a dietary admixture to groups of male and female CD-1 mice at 0, 20, 75, or 300 mg/kg for 92-94 wk; toxicokinetic evaluation was not included in the study. The Drug Metabolism Department designed a study with the objective to retrospectively assess the systemic exposure of male and female CD-1 mice to topiramate administered in the diet for I mo and to determine the dose vs exposure relationship in mice while reproducing the conditions of the carcinogenicity study as closely as possible. The dose levels and regimen duplicated those used in the carcinogenicity study. While the same lot of drug substance used in the original toxicity studies was not available at the time of the ancillary study, a batch that met all the release specifications was used. The dietary admixture was prepared in the same manner as that in the carcinogenicity study utilizing the same equipment (blender, etc.). The concentrations of topiramate in the feed were adjusted to reflect changes in treatment group body weight and food consump-tion throughout the course of the retrospective study, as was done in the carcinogenicity study. A total of 178 mice were used in this ancillary toxicokinetic study with 8 mice/sex assigned to control groups receiving rodent chow and 27 mice/sex randomly assigned to each of the 3 topiramate dosing groups. The topiramate-treated groups received dietary admixtures containing topiramate at concentrations that resulted in doses of 20, 75, and 300 mg/kg/day. On the basis of the concentration of topiramate in the diet and the amount of diet consumed by the mice, it was concluded that the intended doses (20, 75, and 300 mg/kg) were achieved. Single blood samples were taken from groups of mice throughout the 24-hr light/dark cycle after approximately I mo of topiramate administration, when it was assumed steady state had been reached. Plasma samples were analyzed for topiramate using a capillary gas chromatographic assay. The area under the mean plasma concentration vs time curve (AUC) was calculated for a 24-hr interval at approximately I mo into the study by a trapezoidal approximation method for destructive sampling ( 1, 8) .
Mean plasma concentrations of topiramate were plotted against time for a 24-hr light/dark cycle after approximately 1 mo of dosing ( Fig. 2 ). Plasma AUC values are provided in Table I . Because most aspects of the original carcinogenicity study were successfully duplicated, one can conclude that the exposure TABLE IIL-Pharmacokinetic parameters of (+)-tramadol and (-)-tramadol after 14 multiple oral doses (30-mglkgf day) of racemic tramadol hydrochloride to Wistar rats.' I Each value represents mean (SD) or n = 6.° In some cases, there were insufficient timepoints to calculate t,.
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profile established with these mice was representative of the systemic exposure that occurred in the mice in the carcinogenicity study. Mice administered topiramate as a dietary admixture at 20, 75, or 300 mg/kg/day for I mo were systemically exposed continuously to the drug. Statistical analysis comparing male and female groups using the z-test (1, 8) demonstrated that the AUC values for males were significantly greater (^~ 1.7-fold to 4.5-fold) than those for females at each dose level. Exposure to topiramate increased in male and female mice in a dose-related manner and was dose-proportional in some cases (Table I ). The toxicokinetic data generated in this study enabled interpretation of the toxicology findings in the carcinogenicity study. Notable toxicities including centrilobular hypertrophy, gastric hyperplasia, and urinary bladder tumors occurred primarily at the 300-mg/kg/day and sometimes at the 75-mg/kg/day dose, so this is consistent with the higher plasma AUC values at these doses. The data from this ancillary toxicokinetic study also allowed the investigators to determine exposure ratios utilizing known human exposures.
Tramadol monohydrochloride, +/-cis-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol) ( Fig. 3) , is a nonopiate centrally acting, synthetic analgesic compound that was licensed from Gruenenthal GmbH by The R. W. Johnson Pharmaceutical Research Institute for marketing in the United States. Tramadol is a racemic ( 1:1 ) mixture of 2 enantiomers, (+)-and (-)-tramadol with at least 2 mechanisms of action, each differentially distributed in the 2 enantiomers (4). Prior to the last 2-3 yr, all existing pharmacokinetic data were obtained on the racemate using a nonchiral analytical method, because the analytical methodology did not exist to quantitate the individual enantiomers of tramadol in plasma. Once an enantiospecific capillary gas chromatographic/nitrogen phosphorus detection assay method was developed in the Drug Metabolism Department at The R. W. Johnson Pharmaceutical Research Institute, supportive toxicokinetic studies in the toxicology species were initiated. These studies were designed to determine the plasma concentrations of (+)-tramadol and (-)-tramadol enantiomers in the toxicology species and to compare them to plasma concentrations reported in humans at therapeutic doses. The study examining the pharmacokinetics of (+)-tramadol and (-)-tramadol after oral administration of racemic tramadol in the rat serves as an example. Twenty-four Wistar rats were divided into 2 groups of 6 rats/sex for oral gavage dosing of 30 mg/kg/day tramadol hydrochloride for 1 day or 14 consecutive days. Serial blood samples were drawn at 0.5, 1, 2, 4, 7, 10, 14, and 24 hr after administration of the single dose or the fourteenth daily dose for estimation of pharmacokinetic parameters. Plasma samples were analyzed for (+)-tramadol, (-)-tramadol, (+)-M1, and (-)-M 1 (the active 0-desmethyl metabolite of tramadol) using the enantiospecific gas chromatographic/nitrogen phosphorus detection assay method. The 30-mg/kg/day dose corresponds to the high dose utilized in the 18-mo rat toxicity study. The resultant pharmacokinetic parameters are summarized in Tables II-V. Rats were systemically exposed of 30 mg/kg racemic tramadol. Sex differences in pharmacokinetics were observed because female rats exhibited higher (3-6-fold) concentrations of both (+)-tramadol and (-)-tramadol than male rats. Rats were exposed to greater levels of (+)-tramadol than (-)-tramadol, as measured by both maximal plasma concentrations and AUC values after oral administration of racemic tramadol (6) . These data enabled comparisons to newly measured enantiomer levels achieved at therapeutic doses in humans.
Retrospective pharmacokinetic/drug metabolism studies were required following the completion of pilot rat toxicity studies with an experimental osteoporosis drug, RWJ-26138 methylbenzylphosphonate) ( Fig. 4) . Multiple oral administrations of RWJ-26138 (3, 30, or 100 mg/ kg/day) had no effect on animal survival, body weight gain, food consumption, gross and microscopic findings, organ weights, or the results of hematology, clinical chemistry, or urinalysis evaluations. Clinical signs suggestive of a treatment-related effect were limited to salivation [no observed adverse effect level (NOAEL) = 100 mg/kg]. When toxicity is minimal or nonexistent, lack of systemic exposure must be ruled out. Therefore, the following retrospective pharmacokinetic/drug metabolism study was designed.
The objective of the supportive drug metabolism study was to determine the absorption and pharmacokinetics of RWJ-26138 in Sprague-Dawley rats following single or multiple doses. Doses were chosen in the study to include a dose with no observed toxicity and the NOAEL. Two animals/treatment group were administered a single oral gavage dose (10 mg/kg) or a single intravenous dose (tail vein) of 14 C-RWJ-26138. Blood (0-24 hr) and urine (0-144 hr) samples were collected and analyzed for total radioactivity by liquid scintillation counting. Capillary gas chromatography was used to deter-mine the levels of unchanged RWJ-26138 in the plasma. In the multiple-dose segment of the study, daily oral gavage doses (100 mg/kg) of RWJ-26138 were administered to 4 rats for 2 wk. On days 1 and 14 14 C-RWJ-26138 was administered to all of the rats, whereas on the intervening days unlabeled RWJ-26138 was given. Blood (0-24 hr) and urine (0-48 hr) were collected following the first and fourteenth doses and analyzed for total radioactivity, and plasma was analyzed for unchanged drug. For both parts of the study, animals had free access to food in order to mimic the conditions of the toxicity study.
The absolute bioavailability of a single oral dose of RWJ-26138 was approximately 76%, and the terminal elimination half-lives were similar after both iv and oral administration (Table VI) . Multiple oral administration ofRWJ-26138 as compared to single administration resulted in similar values for Cmax and AUC for total radioactivity. However, both Cmax and AUC for unchanged RWJ-26138 were statistically significantly (P < 0.05) lower after 14 days of dosing as compared to day I (Table VII and Fig.  5 ). Multiple oral dosing caused a decrease in the proportion of total radioactivity present as RWJ-26138 and a corresponding increase in the proportion of the dealkylated metabolite, RWJ-27460. Thin-layer chromatography profiling of rat plasma indicated that the major metabolite in rat plasma was RWJ-27460 (monoethyl 3-trifluoromethylbenzylphosphonate ; 41-91 % of the total radioactivity) with only small amounts of parent compound (2-47%) and a minor metabolite, RWJ-26127 (3-triflouromethylbenzylphosphonic acid; 1-10%) (Fig.  4 ). This study suggested that RWJ-26138 induces its own metabolism. The metabolite profiling data support this conclusion. These data allowed the investigators to surmise that the lack of overt toxicity seen after multiple dosing with RWJ-26138 in the rat was due to autoinduction and the resulting low levels of parent compound. Multiple dosing appeared to have no effect on RV~J-26138 absorption. Subsequently, development of RWJ-26138 was halted, and development of its active metabolite, RWJ-26127, was initiated. This retrospective study also demonstrates the very useful information obtained when radiolabeled compound is available (5) .
It may be necessary to quantitate tissue levels of compound and/or metabolite in ancillary studies to explain unusual organ-specific toxicologic findings. For example, Dain and Jaffe (3) examined tissue and plasma levels of fluperlapine, 3-fluoro-6-(4methyl-1-piperazinyl)-11 H-dibenz[b,e]azepine, in the rat to explain differences in toxicological findings with different modes of administration (diet vs gavage) Fluperlapine, a potential agent for the treatment of psychoses, exhibited liver toxicity (moderate to severe hyperlipidosis) when administered to rats via the diet at 40 and 80 mg/kg/day for 12 wk but not when administered by gavage at 80 mg/ kg/day for 12 wks. The rate and extent of exposure of animals to compounds and/or metabolites can vary depending on route of administration. To explain the differences in toxicological findings, the effect of mode of administration (diet vs gavage) on absorption and metabolism was investigated. Regardless of mode of administration, the daily dose (single or multiple) was 80 mg/kg/day of &dquo;C-fiuperlapine. Metabolite patterns were determined by high-performance liquid chromatography in plasma and liver homogenates after I or 15 days. In the multiple-dose studies (diet and gavage), nonradioactive fluperlapine was administered for 10 days and radiolabeled fluperlapine administered for a subsequent 5 days. Animals were sacrificed, and plasma and liver samples were collected at 2 hr after the final gavage dose and immediately following the removal of the radioactive drug-diet. Plasma profiles of total radioactivity and parent and metabolites were also determined after a single administration.
For total radioactivity, the Cmax was greater after gavage vs diet and the shape of the plasma concentration curves quite different. However, the AUC values for total radioactivity were similar after dietary vs gavage administration (Fig. 6 ). The biotransformation results show that the rats were exposed to a different mixture of metabolites depending on the dose regimen (single or multiple) and mode of administration (diet or gavage). After multiple oral doses with drug in diet, 96% of the identified products in the liver were hydroxylated metabolites and only a small amount of parent drug was present. After gavage, the unchanged drug and desmethylfluperlapine together accounted for 54% of the radioactivity in the liver, and hydroxylated metabolites accounted for 44%. A metabolite pattern similar to that already described for liver was observed in the plasma. There was a greater percentage of the hydroxylated metabolites compared to the nonhydroxylated metabolites after diet administration and equal amounts of the hydroxylated and nonhydroxylated metabolites after gavage administration (Table VIII) . The difference in exposure of the liver to hydroxylated vs nonhydroxylated products following administration in diet vs gavage may explain the differences in liver toxicity seen with the different modes of administration.
From the perspective of both pharmaceutical companies and regulatory agencies, the ideal situation is one where toxicokinetic studies are conducted concomitant with the toxicity study. However, there are a number of circumstances when prospective, retrospective, or other ancillary types of toxicokinetic studies are performed as support of toxicity studies. Prospective toxicity studies provide important plasma concentration data that together with toxicity findings can predict the most appropriate doses for long-term studies. The plasma concentration data from prospective studies are often used to predict animal/human exposure ratios. The need for retrospective toxicokinetic studies arises when the original toxicity study was conducted with insufficient plasma concentration determinations or when pilot toxicity studies show lack of toxicity or unusual organ toxicities. When conducting retrospective or ancillary toxicokinetic studies, it is important to duplicate the design of the original toxicology study as closely as possible with respect to dosage levels and regimen, route of administration, formulation, strain/source of animals, and environmental conditions. The ancillary toxicokinetic studies cited provided important information on establishing systemic exposure during long-term toxicity studies, allowing comparisons to human exposures, elucidating compound-related toxicities, and explaining lack of toxicity due to autoinduction and resulting low levels of parent compound.
